VYVGART

(Efgartigimod Alfa)

Phase 2

Argenx

VYVGART is one of 11 biologic programs targeting Encephalitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

EncephalitisRecruiting

EncephalitisPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Encephalitis

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Decadron

AAspen Global Incorporated

Approved

2 3

Acanya

Pfizer

Preclinical

2 4

Opdivo

Bristol-Myers Squibb

Preclinical

1 5

VYVGART

Argenx

Phase 2

1 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Wellcovorin

EEastern Cooperative Oncology Group

Preclinical

2 8

ART5803

AArialys Therapeutics

Phase 2

1 9

Zovirax

BBp Consulting, Inc

Preclinical

1 10

Calculus Bovis Sativus

TTongji Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Encephalitis

NCT07822776

Clinical

Trials by Indication[1]

Encephalitis1 trial

Efficacy and Safety of Efgartigimod in Anti-N-methyl-D-aspartate Receptor Encephalitis: a Phase II Multicenter Single-arm Prospective Pilot Study

Recruiting·BBeijing Tongren Hospital·Phase 2·NCT07822776·20 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 17, 2021

VYVGART

BLA BLA761195

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Efgartigimod Alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Efgartigimod Alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Efgartigimod Alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761195). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Argenx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Argenx

VYVGART

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Encephalitis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News